Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce R Schackman

Showing results (21-30 of 221) with videos related to

Pageof 23
Sort By:
The New England Journal of Medicine|December 28, 2012
Appropriateness criteria and elective procedures--total joint arthroplastyHassan M K Ghomrawi, Bruce R Schackman, Alvin I Mushlin
Journal of General Internal Medicine|July 21, 2019
Hepatitis C Treatment Uptake by New Prescribers After the Introduction of Direct Acting AntiviralsShashi N Kapadia, Phyllis Johnson, Bruce R Schackman, et al.
Journal of Child & Adolescent Substance Abuse|March 9, 2010
An In-Depth Survey of the Screening and Assessment Practices of Highly Regarded Adolescent Substance Abuse Treatment ProgramsJeremy Gans, Mathea Falco, Bruce R Schackman, et al.
Journal of the American Geriatrics Society|November 8, 2006
Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?Lisa A Honkanen, Alvin I Mushlin, Mark Lachs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 6, 2017
State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting AntiviralsShashi N Kapadia, Philip J Jeng, Bruce R Schackman, et al.
Cancer|June 12, 2009
Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancerHeather Taffet Gold, Michael J Hall, Victoria Blinder, et al.
Journal of Substance Use and Addiction Treatment|June 11, 2023
Economic benefits of substance use disorder treatment: A systematic literature review of economic evaluation studies from 2003 to 2021Erminia Fardone, Iván D Montoya, Bruce R Schackman, et al.
Medical Care|March 25, 2020
State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital EventsKatherine Wen, Phyllis Johnson, Philip J Jeng, et al.
Journal of Substance Abuse Treatment|August 25, 2019
Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?Angélica Meinhofer, Arthur Robin Williams, Phyllis Johnson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 22, 2014
Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settingsApril D Kimmel, Daniel W Fitzgerald, Jean W Pape, et al.
Pageof 23

Showing results (21-30 of 221) with videos related to

Sort By:
Pageof 23
The New England Journal of Medicine|December 28, 2012
Appropriateness criteria and elective procedures--total joint arthroplastyHassan M K Ghomrawi, Bruce R Schackman, Alvin I Mushlin
Journal of General Internal Medicine|July 21, 2019
Hepatitis C Treatment Uptake by New Prescribers After the Introduction of Direct Acting AntiviralsShashi N Kapadia, Phyllis Johnson, Bruce R Schackman, et al.
Journal of Child & Adolescent Substance Abuse|March 9, 2010
An In-Depth Survey of the Screening and Assessment Practices of Highly Regarded Adolescent Substance Abuse Treatment ProgramsJeremy Gans, Mathea Falco, Bruce R Schackman, et al.
Journal of the American Geriatrics Society|November 8, 2006
Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?Lisa A Honkanen, Alvin I Mushlin, Mark Lachs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 6, 2017
State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting AntiviralsShashi N Kapadia, Philip J Jeng, Bruce R Schackman, et al.
Cancer|June 12, 2009
Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancerHeather Taffet Gold, Michael J Hall, Victoria Blinder, et al.
Journal of Substance Use and Addiction Treatment|June 11, 2023
Economic benefits of substance use disorder treatment: A systematic literature review of economic evaluation studies from 2003 to 2021Erminia Fardone, Iván D Montoya, Bruce R Schackman, et al.
Medical Care|March 25, 2020
State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital EventsKatherine Wen, Phyllis Johnson, Philip J Jeng, et al.
Journal of Substance Abuse Treatment|August 25, 2019
Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?Angélica Meinhofer, Arthur Robin Williams, Phyllis Johnson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 22, 2014
Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settingsApril D Kimmel, Daniel W Fitzgerald, Jean W Pape, et al.
Pageof 23